Department of Oncology, University of Turin at San Luigi Hospital, Orbassano, Italy.
Department of Medical Sciences, University of Turin, Turin, Italy.
Mod Pathol. 2014 Sep;27(9):1246-54. doi: 10.1038/modpathol.2013.230. Epub 2014 Jan 17.
Mitotic count on hematoxylin and eosin slides is a fundamental morphological criterion in the diagnosis and grading of adrenocortical carcinoma in any scoring system employed. Moreover, it is the unique term strongly associated with patient's prognosis. Phospho-histone H3 is a mitosis-specific antibody, which was already proven to facilitate mitotic count in melanoma and other tumors. Therefore, a study was designed to assess the diagnostic and prognostic role of phospho-histone H3 in 52 adrenocortical carcinomas, comparing manual and computerized count to standard manual hematoxylin- and eosin-based method and Ki-67 index. Manual hematoxylin and eosin and phospho-histone H3 mitotic counts were highly correlated (r=0.9077, P<0.0001), better than computer-assisted phospho-histone H3 evaluations, and had an excellent inter-observer reproducibility at Bland-Altman analysis. Three of 15 cases having <5 mitotic figures per 50 high-power fields by standard count on hematoxylin and eosin gained the mitotic figure point of Weiss Score after a manual count on phospho-histone H3 slides. Traditional mitotic count confirmed to be a strong predictor of overall survival (P=0.0043), better than phospho-histone H3-based evaluation (P=0.051), but not as strong as the Ki-67 index (P<0.0001). The latter further segregated adrenocortical carcinomas into three prognostic groups, stratifying cases by low (<20%), intermediate (20-50%), and high (>50%) Ki-67 values. We conclude that (a) phospho-histone H3 staining is a useful diagnostic complementary tool to standard hematoxylin and eosin mitotic count, enabling optimal mitotic figure evaluation (including atypical mitotic figures) even in adrenocortical carcinomas with a low mitotic index and with a very high reproducibility; (b) Ki-67 proved to be the best prognostic indicator of overall survival, being superior to the mitotic index, irrespective of the method (standard on hematoxylin and eosin or phospho-histone H3-based) used to count mitotic figures.
苏木精和伊红染色切片上的有丝分裂计数是任何评分系统中诊断和分级肾上腺皮质癌的基本形态学标准。此外,它是唯一与患者预后密切相关的术语。磷酸化组蛋白 H3 是一种有丝分裂特异性抗体,已被证明可促进黑色素瘤和其他肿瘤的有丝分裂计数。因此,设计了一项研究来评估磷酸化组蛋白 H3 在 52 例肾上腺皮质癌中的诊断和预后作用,将手动和计算机计数与标准苏木精和伊红染色的手动方法和 Ki-67 指数进行比较。苏木精和伊红染色的手动和磷酸化组蛋白 H3 的有丝分裂计数高度相关(r=0.9077,P<0.0001),优于计算机辅助的磷酸化组蛋白 H3 评估,并且在 Bland-Altman 分析中具有出色的观察者间可重复性。在苏木精和伊红染色的标准计数中,有 15 例中有丝分裂数每 50 个高倍视野<5 个的病例,在磷酸化组蛋白 H3 载玻片上进行手动计数后获得了 Weiss 评分的有丝分裂数点。传统的有丝分裂计数被证实是总生存的强有力预测因素(P=0.0043),优于基于磷酸化组蛋白 H3 的评估(P=0.051),但不如 Ki-67 指数强(P<0.0001)。后者进一步将肾上腺皮质癌分为三个预后组,根据低(<20%)、中(20-50%)和高(>50%)Ki-67 值对病例进行分层。我们得出结论:(a) 磷酸化组蛋白 H3 染色是标准苏木精和伊红有丝分裂计数的有用诊断补充工具,即使在有丝分裂指数较低且具有非常高的可重复性的肾上腺皮质癌中,也能实现最佳的有丝分裂计数(包括不典型有丝分裂计数);(b) Ki-67 被证明是总生存的最佳预后指标,优于有丝分裂指数,无论使用何种方法(苏木精和伊红标准或基于磷酸化组蛋白 H3)计数有丝分裂数。